“The analysis showed that six months after a two-dose BBV152 vaccination series, cell-mediated immunity and neutralizing antibodies to both homologous (D614G) and heterologous strains (Alpha, Beta, Delta, and Delta plus) persisted above baseline, although the magnitude of the responses had declined,” the vaccine manufacturer said in a statement.
It added that the neutralizing antibodies against homologous and heterologous SARS-CoV-2 variants increased 19 to 265-fold after a third vaccination.
“Booster BBV152 vaccination is safe and may be necessary to ensure persistent immunity to prevent breakthrough infections,” said the vaccine manufacturer.
Krishna Ella, Chairman and Managing Director at Bharat Biotech, said, “These trial results provide a strong foundation towards our goal to provide Covaxin as a booster dose. Our goal of developing a global vaccine against COVID-19 has been achieved. Covaxin is now indicated for adults, children, 2-dose primary and booster doses. This enables the use of Covaxin as a universal vaccine.”
Based on emerging data, Bharat Biotech believes that a third dose may be beneficial to maintain the highest levels of protection, he added.
Source: IANS
